MGMT promoter methylation is a strong prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma

• Verfasst von: Weller, Michael [VerfasserIn]
• Verfasst von: Kästner, Bärbel [VerfasserIn]
• Verfasst von: Wick, Antje [VerfasserIn]
• Verfasst von: Platten, Michael [VerfasserIn]
• Verfasst von: Hüsing, Johannes [VerfasserIn]
• Verfasst von: Wick, Wolfgang [VerfasserIn]
• Titel: MGMT promoter methylation is a strong prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma
• Titelzusatz: The DIRECTOR trial
• Verf.angabe: Michael Weller, Ghazaleh Tabatabai, Bärbel Kästner, Jörg Felsberg, Joachim P. Steinbach, Antje Wick, Oliver Schnell, Peter Hau, Ulrich Herrlinger, Michael C. Sabel, Hans-Georg Wirsching, Ralf Ketter, Oliver Bähr, Michael Platten, Jörg C. Tonn, Uwe Schlegel, Christine Marosi, Roland Goldbrunner, Roger Stupp, Krisztian Homicsko, Josef Pichler, Guido Nikkhah, Jürgen Meixensberger, Peter Vajkoczy, Spyros Kollias, Johannes Hüsing, Guido Reifenberger, Wolfgang Wick
• Umfang: 8 S.
• Fussnoten: Gesehen am 29.06.2017
• Titel Quelle: Enthalten in: Clinical cancer research
• Jahr Quelle: 2015
• Band/Heft Quelle: 21(2015), 9, S. 2057-2064
• ISSN Quelle: 1557-3265
• DOI: doi:10.1158/1078-0432.CCR-14-2737
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1560327316

Abstract

Purpose: Rechallenge with temozolomide (TMZ) at first progression of glioblastoma after temozolomide chemoradiotherapy (TMZ/RT→TMZ) has been studied in retrospective and single-arm prospective studies, applying temozolomide continuously or using 7/14 or 21/28 days schedules. The DIRECTOR trial sought to show superiority of the 7/14 regimen. Experimental Design: Patients with glioblastoma at first progression after TMZ/RT→TMZ and at least two maintenance temozolomide cycles were randomized to Arm A [one week on (120 mg/m2 per day)/one week off] or Arm B [3 weeks on (80 mg/m2 per day)/one week off]. The primary endpoint was median time-to-treatment failure (TTF) defined as progression, premature temozolomide discontinuation for toxicity, or death from any cause. O6-methylguanine DNA methyltransferase (MGMT) promoter methylation was prospectively assessed by methylation-specific PCR. Results: Because of withdrawal of support, the trial was prematurely closed to accrual after105 patients. There was a similar outcome in both arms for median TTF [A: 1.8 months; 95% confidence intervals (CI), 1.8-3.2 vs. B: 2.0 months; 95% CI, 1.8-3.5] and overall survival [A: 9.8 months (95% CI, 6.7-13.0) vs. B: 10.6 months (95% CI, 8.1-11.6)]. Median TTF in patients with MGMT-methylated tumors was 3.2 months (95% CI, 1.8-7.4) versus 1.8 months (95% CI, 1.8-2) in MGMT-unmethylated glioblastoma. Progression-free survival rates at 6 months (PFS-6) were 39.7% with versus 6.9% without MGMT promoter methylation. Conclusions: Temozolomide rechallenge is a treatment option for MGMT promoter-methylated recurrent glioblastoma. Alternative strategies need to be considered for patients with progressive glioblastoma without MGMT promoter methylation. Clin Cancer Res; 21(9); 2057-64. ©2015 AACR.